Tirzepatide is a once-weekly injectable compound that activates two hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). The FDA has approved it as Mounjaro, used alongside diet and exercise to manage blood sugar in adults with type 2 diabetes, and as Zepbound, for chronic weight management in adults with obesity, or overweight with a weight-related health condition, and for moderate to severe obstructive sleep apnea in adults with obesity.
A plain-language look at what the FDA-approved trial data shows, for research review only, not for personal use.
Tirzepatide side effects are unusually well documented. Two large medical studies, one looking at weight management and one at type 2 diabetes, fed directly into the FDA-approved drug labels for the compound, and those labels list exactly what side effects showed up and how often. Researchers studying what tirzepatide is use this same label data to understand how the drug behaves in the body. This brief translates the label numbers into plain language, without the jargon that usually surrounds them. It is written for research review, not as guidance for any person considering use.
How the Trial Record Logs Side Effects
During the studies, everyone taking part reported symptoms on a set schedule, and doctors running the trial noted how serious each one was. Each report was then sorted by dose, so researchers can see exactly which side effect showed up at which dose, and how that compares with people taking a placebo, meaning an inactive shot used only for comparison.
Here is the useful part for anyone reading the data side by side. The two studies did not report the same numbers:
- Digestive side effects were reported more often in the weight management study than in the diabetes study.
- This pattern held true across nausea, diarrhea, and vomiting specifically.
- Researchers think part of the gap comes from differences between the two groups of participants, not from the drug acting differently depending on why someone might use it.
See also: Semaglutide vs Tirzepatide, How the Research Compares
Digestive Side Effects by the Numbers
The FDA-approved prescribing label for Zepbound (tirzepatide), NDA 217806, the weight management version of the drug, breaks down exactly how common digestive side effects were. In plain terms:
- Any digestive side effect: reported by 56 out of 100 people on the drug, compared with 30 out of 100 on placebo.
- Nausea: 25 to 29 out of 100 people on the drug, compared with 8 out of 100 on placebo.
- Diarrhea: 19 to 23 out of 100, compared with 8 out of 100 on placebo.
- Vomiting: 8 to 13 out of 100, compared with 2 out of 100 on placebo.
- Constipation: 11 to 17 out of 100 people on the drug, compared with 5 out of 100 on placebo. At the lowest dose this is actually more common than vomiting, so it is not always the smallest of the four.
Nausea, diarrhea, vomiting, and constipation rates by dose, compared with placebo (out of 100 people):
| Side Effect | Placebo (out of 100 people) |
5 mg (out of 100 people) |
10 mg (out of 100 people) |
15 mg (out of 100 people) |
|---|---|---|---|---|
| Nausea | 8 | 25 | 29 | 28 |
| Diarrhea | 8 | 19 | 21 | 23 |
| Vomiting | 2 | 8 | 11 | 13 |
| Constipation | 5 | 17 | 14 | 11 |
The timing matters too. The label notes that most nausea, vomiting, and diarrhea happened while the dose was still being increased, and eased off once someone settled onto a steady dose.
See also: Retatrutide vs Tirzepatide, What Sets Them Apart
How the Step-Up Dosing Schedule Works
The FDA-approved schedule in the Mounjaro (tirzepatide) prescribing label, NDA 215866, starts small and increases gradually. It looks like this:
- Week 1: start at 2.5 mg once a week, a dose meant only to begin treatment.
- Week 5: after four weeks at 2.5 mg, increase to 5 mg once a week.
- After that, the dose can go up by 2.5 mg at a time, but only after at least four weeks on the current dose.
- The highest labeled dose is 15 mg once a week.
The step-up schedule from the FDA-approved label:
| Week | Weekly Dose |
|---|---|
| 1 | 2.5 mg |
| 5 | 5 mg |
| 9 | 7.5 mg |
| 13 | 10 mg |
| 17 | 12.5 mg |
| 21 | 15 mg (highest dose studied) |
This same step-up structure is worth reading next to the tirzepatide dosage and reconstitution guide, since each step up lines up with a fresh wave of digestive reports in the trial data.
Stopping the drug followed the same step pattern. Between 5 and 7 out of 100 people stopped taking it because of a side effect, compared with 3 out of 100 on placebo, with the rate climbing at each higher dose.
A Boxed Warning About Thyroid Tumors
The most serious item in the tirzepatide record is not a percentage at all.
Boxed Warning. The FDA label carries a boxed warning, the agency’s strongest label warning category, about a possible risk of thyroid C-cell tumors. That warning traces back to findings in rodent studies rather than to a confirmed pattern in human trial participants, but it is treated seriously enough that the label lists a personal or family history of medullary thyroid carcinoma, or a related condition called MEN 2, as a reason the drug should not be used at all.
Researchers reading the tirzepatide safety record should treat this warning as a structural feature of the label rather than as a side effect with an incidence rate attached to it.
How Combination Use Changes the Risk
Tirzepatide’s own low blood sugar signal looks modest on its own, about 4 out of 100 people on the drug alone versus roughly 1 out of 100 on placebo. That number changes sharply once tirzepatide is paired with another diabetes drug. Combined with a sulfonylurea, an older class of diabetes medication, the reported rate rises to roughly 10 out of 100. Combined with insulin, it climbs further, to somewhere between 14 and 19 out of 100.
See also: Tirzepatide Dosage & Reconstitution Research Guide
What the Data Still Leaves Open
Some rarer side effects are harder to draw firm conclusions about. The Zepbound (tirzepatide) prescribing label, NDA 217806, reports pancreas inflammation, called pancreatitis, in about 2 out of 1,000 people on the drug, the same rate as on placebo. That does not clearly point to the drug as the cause.
Gallbladder problems, tracked in the same label, tell a slightly different story. Compared with placebo, slightly more people on the drug reported gallstones, gallbladder inflammation, and gallbladder removal surgery:
| Event | Placebo (per 1,000 people) |
Tirzepatide (per 1,000 people) |
|---|---|---|
| Gallstones | 10 | 11 |
| Gallbladder inflammation | 2 | 7 |
| Gallbladder removal surgery | 0.2 | 2 |
The gap is small on each measure, but it points the same direction across all three.
There is also a newer piece of the picture the original studies could not capture. On 29 January 2026, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) strengthened its warning on acute pancreatitis, including rare necrotising and fatal cases, across the whole GLP-1 and dual GLP-1/GIP receptor agonist drug class, tirzepatide included. That update was built on 1,296 UK pancreatitis reports logged between 2007 and October 2025 through the Yellow Card scheme, the UK’s system for voluntary post-market side effect reports, not on new trial data.
Why This Matters for Study Design
For a research team planning a new tirzepatide study, this label data works better as a planning guide than as a final verdict on risk. Since digestive side effects cluster around each dose increase, it makes sense to check in with participants right around those points rather than on a fixed weekly schedule. Since people are more likely to stop the drug at higher doses, a study can build in a way to pause or hold a dose steady when early symptoms show up.
The gap between the weight management and diabetes studies is also worth planning around. A study modeled on the weight loss research space should expect a higher starting rate of digestive side effects than one modeled on the diabetes studies.
Research Use Disclaimer
This content is provided for Research Use Only (RUO). The compounds discussed are not drugs, dietary supplements, foods, or cosmetics, and are not intended for human or animal consumption, diagnostic use, or therapeutic use of any kind. They have not been evaluated by the FDA for safety or efficacy in humans. Any research use must be conducted by qualified professionals in a controlled laboratory environment, in accordance with all applicable institutional, local, and federal regulations.
Sources for the numbers above: the U.S. FDA-approved prescribing labels for Zepbound (tirzepatide), NDA 217806, and Mounjaro (tirzepatide), NDA 215866, both accessed 3 September 2026; and the MHRA Drug Safety Update named above, published 29 January 2026.
